MolGenie has currently been assigned the rights to develop and commercialize the rights to a EU-PCT patent application claiming treatments for NPY1R overexpressing cancers using peptide-drug-conjugates from its inventors. Thus, MolGenie is delighted to develop this exciting new drug discovery project – aiming at a treatment for NPY1R related cancers like Ewing sarcoma, triple negative breast cancers (TNBC) and other cancers.
The described peptide-drug-conjugates of the invention have already shown efficacy in animal models of NPY1R overexpresing cancers. Thus, MolGenie has been active to synthesize larger amounts of its PDC molecules for more and in-depths preclinical testing in larger scale in vitro and in vivo assays.